Dyslipidemia, statins and prostate cancer

Expert Review of Anticancer Therapy

Volumn 12, Issue 7, 2012, Pages 981-990

  Rice, Kevin R ^a   Koch, Michael O ^a   Cheng, Liang ^a   Masterson, Timothy A ^a  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

dyslipidemia; HMG CoA reductase inhibitors; metabolic syndrome; prostate cancer; statins

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ACYL COENZYME A; ACYL COENZYME A1; ACYL COENZYME A2; ANDROGEN RECEPTOR; ATORVASTATIN; CHOLESTEROL; CHOLESTEROL SULFATE; EPIDERMAL GROWTH FACTOR RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVINOLIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER INCIDENCE; CANCER INVASION; CANCER RISK; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; DRUG USE; DYSLIPIDEMIA; ENZYME ACTIVITY; G1 PHASE CELL CYCLE CHECKPOINT; HIGH RISK POPULATION; HUMAN; ISOPRENYLATION; LIPID BLOOD LEVEL; LIPID RAFT; LIPID TRANSPORT; LIPOGENESIS; METASTASIS; NONHUMAN; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; REVIEW;

ADENOCARCINOMA; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHOLESTEROL; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LIPOGENESIS; MALE; MEMBRANE MICRODOMAINS; MICE; PRENYLATION; PROSTATECTOMY; PROSTATIC NEOPLASMS; RATS; TREATMENT OUTCOME;

EID: 84864576472     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.75     Document Type: Review

References (73)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61(4), 212-236 (2011).
2. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J. Natl Cancer Inst. 92(24), 2009-2017 (2000).
3. Whittemore AS, Wu AH, Kolonel LN et al. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am. J. Epidemiol. 141(8), 732-740 (1995).
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel On Detection, Evaluation, And Treatment Of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285(19), 2486-2497 (2001).
5. Moradi T, Delfino RJ, Bergstrom SR, Yu ES, Adami HO, Yuen J. Cancer risk among Scandinavian immigrants to the US and Scandinavian residents compared with US whites, 1973-1989. Eur. J. Cancer Prev. 7(2), 117-125 (1998).
6. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003-2004. Am. Heart J. 156(1), 112-119 (2008).
7. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: Impact of the 2001 National Cholesterol Education Program guidelines. Ann. Pharmacother. 42(9), 1208-1215 (2008).
8. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267-1278 (2005).
9. Magura L, Blanchard R, Hope B, Beal JR, Schwartz GG, Sahmoun AE. Hypercholesterolemia and prostate cancer: A hospital-based case-control study. Cancer Causes Control 19(10), 1259-1266 (2008).
10. Platz EA, Till C, Goodman PJ et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol. Biomarkers Prev. 18(11), 2807-2813 (2009).
11. Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. Int. J. Cancer 123(7), 1693-1698 (2008).
12. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II Cohort. Cancer Causes Control 21(1), 61-68 (2010).
13. Ulmer H, Borena W, Rapp K et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br. J. Cancer 101(7), 1202-1206 (2009).
14. Van Hemelrijck M, Garmo H, Holmberg L et al. Prostate cancer risk in the Swedish AMORIS study: The interplay among triglycerides, total cholesterol, and glucose. Cancer 117(10), 2086-2095 (2011).
15. Henriksson P, Eriksson M, Ericsson S et al. Hypocholesterolaemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostate. Lancet 2(8673), 1178-1180 (1989).
16. Chen SS, Chen KK, Lin AT, Chang YH, Wu HH, Chang LS. Correlation between pretreatment serum biochemical markers and treatment outcome for prostatic cancer with bony metastasis. J. Chin. Med. Assoc. 72(6), 301-306 (2009).
17. Thysell E, Surowiec I, Hornberg E et al. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS ONE 5(12), e14175 (2010).
18. Platz EA, Leitzmann MF, Visvanathan K et al. Statin drugs and risk of advanced prostate cancer. J. Natl Cancer Inst. 98(24), 1819-1825 (2006).
19. Vainio P, Lehtinen L, Mirtti T et al. Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget 2(12), 1176-1190 (2011).
20. Banez LL, Klink JC, Jayachandran J et al. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol. Biomarkers Prev. 19(3), 722-728 (2010).
21. Freeman MR, Solomon KR. Cholesterol and prostate cancer. J. Cell. Biochem. 91(1), 54-69 (2004).
22. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Statins and cancer risk: A literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J. Clin. Oncol. 24(30), 4808-4817 (2006).
23. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. Eur. J. Cancer 44(15), 2122-2132 (2008).
24. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. Int. J. Cancer 123(4), 899-904 (2008).
25. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin use and risk of prostate cancer: Results from a population-based epidemiologic study. Am. J. Epidemiol. 168(3), 250-260 (2008).
26. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA. Screening statins for possible carcinogenic risk: Up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol. Drug Saf. 17(1), 27-36 (2008).
27. Haukka J, Sankila R, Klaukka T et al. Incidence of cancer and statin usage - record linkage study. Int. J. Cancer 126(1), 279-284 (2010).
28. Boudreau DM, Yu O, Buist DS, Miglioretti DL. Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control 19(7), 767-774 (2008).
29. Farwell WR, Scranton RE, Lawler EV et al. The association between statins and cancer incidence in a veterans population. J. Natl Cancer Inst. 100(2), 134-139 (2008).
30. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: A population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 16(11), 2226-2232 (2007).
31. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol. Biomarkers Prev. 16(11), 2213-2217 (2007).
32. Loeb S, Kan D, Helfand BT, Nadler RB, Catalona WJ. Is statin use associated with prostate cancer aggressiveness? BJU Int. 105(9), 1222-1225 (2010).
33. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J. Clin. Oncol. 28(16), 2653-2659 (2010).
34. Hamilton RJ, Banez LL, Aronson WJ et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 116(14), 3389-3398 (2010).
35. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J. Natl Cancer Inst. 100(21), 1511-1518 (2008).
36. Mondul AM, Selvin E, De Marzo AM, Freedland SJ, Platz EA. Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. Cancer Causes Control 21(5), 671-678 (2010).
37. Pazzaglia S, Saran A, Pariset L et al. Sensitivity of C3H 10T1/2 cells to radiation-induced killing and neoplastic transformation as a function of cell cycle. Int. J. Radiat. Biol. 69(1), 57-65 (1996).
38. Langley RE, Quartuccio SG, Kennealey PT, Coleman CN, Bump EA. Effect of cell cycle stage, dose rate and repair of sublethal damage on radiation-induced apoptosis in F9 teratocarcinoma cells. Radiat. Res. 144(1), 90-96 (1995).
39. Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 51(13), 3602-3609 (1991).
40. Sivaprasad U, Abbas T, Dutta A. Differential efficacy of 3-hydroxy-3- methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol. Cancer Ther. 5(9), 2310-2316 (2006).
41. Miller AC, Kariko K, Myers CE, Clark EP, Samid D. Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int. J. Cancer 53(2), 302-307 (1993).
42. Moyad MA, Merrick GS, Butler WM et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 66(6), 1150-1154 (2005).
43. Soto DE, Daignault S, Sandler HM, Ray ME. No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 73(1), 158-162 (2009).
44. Mondul AM, Caffo B, Platz EA. Minimal detection bias in the inverse association between statin drug use and advanced prostate cancer risk: A simulation study. Cancer Epidemiol. 35(4), e6-e11 (2011).
45. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am. J. Epidemiol. 164(11), 1094-1102 (2006).
46. Chen Y, Hughes-Fulford M. Human prostate cancer cells lack feedbackregulation of low-density lipoprotein receptor and its regulator, SREBP2. Int. J. Cancer 91(1), 41-45 (2001).
47. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J. Clin. Invest. 115(4), 959-968 (2005).
48. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2(7), 489-501 (2002).
49. Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR. Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res. 62(8), 2227-2231 (2002).
50. Huggins C, Hodges CV. Studies of prostatic cancer I The effect of castration, of estrogen and of androgen injection on serum phophatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293-297 (1941).
51. Cinar B, Mukhopadhyay NK, Meng G, Freeman MR. Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains. J. Biol. Chem. 282(40), 29584-29593 (2007).
52. Swinnen JV, Ulrix W, Heyns W, Verhoeven G. Coordinate regulation of lipogenic gene expression by androgens: Evidence for a cascade mechanism involving sterol regulatory element binding proteins. Proc. Natl Acad. Sci. USA 94(24), 12975-12980 (1997).
53. Swinnen JV, Van Veldhoven PP, Esquenet M, Heyns W, Verhoeven G. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 137(10), 4468-4474 (1996).
54. Roy M, Kung HJ, Ghosh PM. Statins and prostate cancer: Role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am. J. Cancer Res. 1(4), 542-561 (2011).
55. Ghosh PM, Ghosh-Choudhury N, Moyer ML et al. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene 18(28), 4120-4130 (1999).
56. Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem. Biophys. Res. Commun. 269(3), 652-659 (2000).
57. Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol. Biomarkers Prev. 17(1), 88-94 (2008).
58. Parikh A, Childress C, Deitrick K, Lin Q, Rukstalis D, Yang W. Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells. Prostate 70(9), 971-981 (2010).
59. Leon C, Hill JS, Wasan KM. Potential role of acyl-coenzyme A:cholesterol transferase (ACAT) inhibitors as hypolipidemic and antiatherosclerosis drugs. Pharm. Res. 22(10), 1578-1588 (2005).
60. Locke JA, Wasan KM, Nelson CC, Guns ES, Leon CG. Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A: Cholesterol acyltransferase (ACAT). Prostate 68(1), 20-33 (2008).
61. Eberlin LS, Dill AL, Costa AB et al. Cholesterol sulfate imaging in human prostate cancer tissue by desorption electrospray ionization mass spectrometry. Anal. Chem. 82(9), 3430-3434 (2010).
62. Kiguchi K, Iwamori M, Yamanouchi S, Ishiwata I, Saga M, Amemiya A. Coexpression of cholesterol sulfate and cytokeratin as tumor markers in well-differentiated squamous cell carcinoma of the human uterine cervix. Clin. Cancer Res. 4(12), 2985-2990 (1998).
63. Rearick JI, Stoner GD, George MA, Jetten AM. Cholesterol sulfate accumulation in tumorigenic and nontumorigenic rat esophageal epithelial cells: Evidence for defective differentiation control in tumorigenic cells. Cancer Res. 48(18), 5289-5295 (1988).
64. Epstein EH, Williams ML, Elias PM. The epidermal cholesterol sulfate cycle. J. Am. Acad. Dermatol. 10(5 Pt 1), 866-868 (1984).
65. Roberts KD, Bandi L, Calvin HI, Drucker WD, Lieberman S. Evidence that steroid sulfates serve as biosynthetic intermediates. IV. Conversion of cholesterol sulfate in vivo to urinary C19 and C21 steroidal sulfates. Biochemistry 3, 1983-1988 (1964).
66. Roberts KD, Bandi L, Lieberman S. The conversion of cholesterol-3H- sulfate-35S into pregnenolone-3H-sulfate-35S by sonicated bovine adrenal mitochondria. Biochem. Biophys. Res. Commun. 29, 6 (1967).
67. Young DG, Hall PF. The side-chain cleavage of cholesterol and cholesterol sulfate by enzymes from bovine adrenocortical mitochondria. Biochemistry 8(7), 2987-2997 (1969).
68. Hochberg RB, Ladany S, Welch M, Lieberman S. Cholesterol and cholesterol sulfate as substrates for the adrenal side-chain cleavage enzyme. Biochemistry 13(9), 1938-1945 (1974).
69. Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res. 68(11), 4447-4454 (2008).
70. Ponec M, Havekes L, Kempenaar J, Vermeer BJ. Cultured human skin fibroblasts and keratinocytes: Differences in the regulation of cholesterol synthesis. J. Invest. Dermatol. 81(2), 125-130 (1983).
71. Bleau G, Lalumiure G, Chapdelaine A, Roberts K. Red cell surface structure. Stabilization by cholesterol sulfate as evidenced by scanning electron microscopy. Biochim. Biophys. Acta 375(2), 220-223 (1975).
72. Bleau G, Bodley FH, Longpre J, Chapdelaine A, Roberts KD. Cholesterol sulfate I Occurrence and possible biological function as an amphipathic lipid in the membrane of the human erythrocyte. Biochim. Biophys. Acta 352(1), 1-9 (1974).
73. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 364(18), 1708-1717 (2011).